Role of TXA in Patients Undergoing Breast Free Flap Reconstruction

Launched by UNIVERSITY OF VIRGINIA · May 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called tranexamic acid (TXA) in women who are undergoing a specific type of breast surgery known as free flap reconstruction. TXA is used to help reduce bleeding during and after surgery. In this study, some participants will receive TXA while others will not, allowing researchers to compare outcomes such as blood loss, need for blood transfusions, and any complications that may arise during recovery. The goal is to see if using TXA can improve surgical results and reduce complications for patients.

To be eligible for this trial, participants must be female, at least 18 years old, and scheduled for either unilateral or bilateral abdomen-based breast reconstruction at UVA Medical Center. Women who have certain medical conditions, are allergic to TXA, or have low blood counts will not be able to participate. Those who join the study can expect to receive standard surgical care and will be closely monitored throughout the process. This trial aims to provide clearer information on how TXA can benefit patients undergoing this type of surgery.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • All female patients who are 18 years or older who will undergo unilateral or bilateral abdomen-based free flap breast reconstruction at UVA Medical Center
• Exclusion Criteria:
• • Subjects with ages \<18 years
• • Allergy to TXA
• • Subjects who has contraindications to TXA: anyone who has active intravascular thrombosis or anyone with subarachnoid hemorrhage
• • Subjects who have anemia (defined as baseline hemoglobin \<8 g/dL
• • Subjects who cannot read or understand English
• • Subjects who are pregnant